AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16784623 — intervention group
Group type: COMPARATOR
Intervention: THA with standard posterolateral incision (Group 2)
Number of subjects: 120
Study 15301774 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic muscle actions
Number of subjects: 10
Study 15301774 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric muscle actions
Number of subjects: 10
Study 10845879 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene (60 mg/d)
Number of subjects: 24
Study 10845879 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogen (0.625 mg/d)
Number of subjects: 24
Study 8764787 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (0.75% bupivacaine)
Number of subjects: 138
Study 8764787 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (2% lidocaine and 0.75% bupivacaine plus hyaluronidase)
Number of subjects: 138
Study 8764787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Topical and Retrobulbar)
Number of subjects: 138
Study 1481550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 31
Study 1481550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 31
Study 1481550 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam/Placebo (group A)
Number of subjects: 31
Study 31849170 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased daily walking steps for 6 months
Number of subjects: 91
Study 31849170 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 91
Study 29903515 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (E/S)
Number of subjects: 14819
Study 29903515 — intervention group
Group type: COMPARATOR
Intervention: placebo/simvastatin (P/S)
Number of subjects: 14819
Study 29903515 — intervention group
Group type: EXPERIMENTAL
Intervention: NFS > 0.67
Number of subjects: 14819
Study 29903515 — intervention group
Group type: COMPARATOR
Intervention: NFS < -1.455
Number of subjects: 14819
Study 28395364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Paracetamol
Number of subjects: 80
Study 28395364 — intervention group
Group type: COMPARATOR
Intervention: Oral Ibuprofen
Number of subjects: 80
Study 26238113 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4mg (n = 9)
Number of subjects: 33
Study 26238113 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80mg/d (n = 9)
Number of subjects: 33
Study 26238113 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (n = 15)
Number of subjects: 33
Study 24204974 — intervention group
Group type: EXPERIMENTAL
Intervention: Story booklets
Number of subjects: 413
Study 24204974 — intervention group
Group type: COMPARATOR
Intervention: Standard information sheets
Number of subjects: 413
Study 22022848 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person, targeted education
Number of subjects: 24
Study 22022848 — intervention group
Group type: COMPARATOR
Intervention: Delayed education (control)
Number of subjects: 24
Study 18837771 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-48 (7.5 g/d, n=22)
Number of subjects: 42
Study 18837771 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 42
Study 17076223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bisoprolol and enalapril with trimetasidine (70 mg/day from postmyocardial day 7-10 for 6 months)
Number of subjects: 75
Study 17076223 — intervention group
Group type: COMPARATOR
Intervention: Combination of bisoprolol and enalapril without trimetasidine
Number of subjects: 75
Study 12687510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse specialist care
Number of subjects: 210
Study 12687510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient care
Number of subjects: 210
Study 12687510 — intervention group
Group type: EXPERIMENTAL
Intervention: Day patient care
Number of subjects: 210
Study 12687510 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction (VAS)
Number of subjects: 210
Study 12687510 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire (total group)
Number of subjects: 210
Study 12411847 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypodermoclysis with 1000 ml 5% dextrose in water infusion plus 140 mEq/L sodium chloride at 42 ml/hour per day
Number of subjects: 42
Study 12411847 — intervention group
Group type: COMPARATOR
Intervention: Standard care with subcutaneous drugs (haloperidol 2.5 mg every 4 hours and/or metoclopramide 10 mg every 4 hours)
Number of subjects: 42
Study 8636591 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot
Number of subjects: 30
Study 8636591 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard low-heeled shoes (walking shoes)
Number of subjects: 30
Study 8636591 — intervention group
Group type: COMPARATOR
Intervention: Standard high-heeled shoes
Number of subjects: 30
Study 8636591 — intervention group
Group type: COMPARATOR
Intervention: Own shoes
Number of subjects: 30
Study 1524115 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5%
Number of subjects: 0
Study 1524115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6385678 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (149 +/- 11 mg daily)
Number of subjects: 62
Study 6385678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3711771 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast screening
Number of subjects: 132
Study 3711771 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent self-examination (more than once a month)
Number of subjects: 132
Study 28678111 — intervention group
Group type: EXPERIMENTAL
Intervention: Batroxobin (Group B)
Number of subjects: 100
Study 28678111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) (Group T)
Number of subjects: 100
Study 28678111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Batroxobin and Tranexamic Acid (Group BT)
Number of subjects: 100
Study 28678111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 100
Study 27376940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring graft
Number of subjects: 33
Study 27376940 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon graft
Number of subjects: 33
Study 25576896 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of injectable powder of pure HSYA (IPPH) at doses of 25, 50, and 75 mg
Number of subjects: 36
Study 25576896 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 50 mg IPPH, once daily for 7 consecutive days
Number of subjects: 36
Study 25576896 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and multiple dosing of IPPH
Number of subjects: 36
Study 22731399 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 mg)
Number of subjects: 64
Study 22731399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19926718 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg nalfurafine hydrochloride
Number of subjects: 337
Study 19926718 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg nalfurafine hydrochloride
Number of subjects: 337
Study 19926718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 18972781 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity of 100 mW/cm2
Number of subjects: 0
Study 18972781 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity of 300 mW/cm2
Number of subjects: 0
Study 18972781 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity of 500 mW/cm2
Number of subjects: 0
Study 18972781 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity of 600 mW/cm2 (used for polymerization after bonding)
Number of subjects: 0
Study 16649881 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-system therapy (SST)
Number of subjects: 45
Study 16649881 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy (CT)
Number of subjects: 45
Study 14636195 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% hydroquinone combined with 10% buffered glycolic acid, vitamins C and E, and sunscreen
Number of subjects: 39
Study 14636195 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen alone
Number of subjects: 39
Study 10895397 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (100 or 200 mg three times daily)
Number of subjects: 24
Study 8644624 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral sotalol
Number of subjects: 0
Study 1378685 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (3000ng infused into the graft)
Number of subjects: 0
Study 6378158 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine hydrochloride nose drops or nasal spray
Number of subjects: 152
Study 6378158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 31752756 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-8 model for preoperative risk stratification
Number of subjects: 748
Study 31752756 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-8 model
Number of subjects: 748
Study 28554375 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based psychoeducative intervention
Number of subjects: 20
Study 24889731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 12
Study 24889731 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin (5 mg)
Number of subjects: 12
Study 24889731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both gliptins (Sitagliptin and Saxagliptin)
Number of subjects: 12
Study 24889731 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (2 mg)
Number of subjects: 12
Study 23916998 — intervention group
Group type: EXPERIMENTAL
Intervention: 5h sleep restriction
Number of subjects: 28
Study 23916998 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 28
Study 23916998 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg caffeine
Number of subjects: 28
Study 23916998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21859060 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine hydrochloride
Number of subjects: 60
Study 21859060 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine hydrochloride
Number of subjects: 60
Study 21859060 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline solution)
Number of subjects: 60
Study 19251141 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary posterior continuous curvilinear capsulorhexis with posterior optic buttonholing (PCCC-POBH)
Number of subjects: 30
Study 19251141 — intervention group
Group type: COMPARATOR
Intervention: Primary posterior continuous curvilinear capsulorhexis (PCCC) without posterior optic buttonholing
Number of subjects: 30
Study 16955184 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical morphine gel 0.3%
Number of subjects: 28
Study 16955184 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 28
Study 14695665 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of specific viruses in middle ear fluids and nasopharyngeal aspirates
Number of subjects: 940
Study 14695665 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of rhinoviruses, enteroviruses, and respiratory syncytial virus (RSV)
Number of subjects: 940
Study 14695665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall virus detection methods
Number of subjects: 940
Study 14695665 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-based methods for virus detection
Number of subjects: 940
Study 11509270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 200
Study 11509270 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia (parenteral opiates)
Number of subjects: 200
Study 9928856 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of aprotinin (Group B)
Number of subjects: 20
Study 9928856 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 20
Study 9928856 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial infection (Group C)
Number of subjects: 20
Study 9928856 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Inflammatory Response Syndrome (SIRS) (Group D)
Number of subjects: 20
Study 7988583 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic solution injected into the perivascular axillary sheath (12 ml of a mixture of equal parts of 0.5% bupivacaine with 1:200,000 adrenaline and 2% lignocaine)
Number of subjects: 40
Study 2472337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 100
Study 2472337 — intervention group
Group type: COMPARATOR
Intervention: Stitches
Number of subjects: 100
Study 1102232 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (1 mg)
Number of subjects: 262
Study 1102232 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (2 mg)
Number of subjects: 262
Study 1102232 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (4 mg)
Number of subjects: 262
Study 1102232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (30 mg)
Number of subjects: 262
Study 1102232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (60 mg)
Number of subjects: 262
Study 30630555 — intervention group
Group type: EXPERIMENTAL
Intervention: group rumination-focused cognitive-behavioural therapy (RFCBT)
Number of subjects: 131
Study 30630555 — intervention group
Group type: COMPARATOR
Intervention: group CBT
Number of subjects: 131
Study 31385880 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure 24 cm H2O and low pressure 20 cm H2O (very high positive end-expiratory pressure-very low driving pressure)
Number of subjects: 16
Study 31385880 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure 24 cm H2O and low pressure 5 cm H2O (low positive end-expiratory pressure-high driving pressure)
Number of subjects: 16
Study 31385880 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure 17 cm H2O and low pressure 5 cm H2O (low positive end-expiratory pressure-low driving pressure)
Number of subjects: 16
Study 28727887 — intervention group
Group type: EXPERIMENTAL
Intervention: YAG laser vitreolysis
Number of subjects: 52
Study 28727887 — intervention group
Group type: COMPARATOR
Intervention: Sham YAG (control)
Number of subjects: 52
Study 26562591 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (ABI)
Number of subjects: 124
Study 26562591 — intervention group
Group type: COMPARATOR
Intervention: Screening alone (Control)
Number of subjects: 124
Study 23760160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm selection before freezing with hypotaurine supplementation (S-F/H+)
Number of subjects: 64
Study 23760160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm selection before freezing without hypotaurine supplementation (S-F/H-)
Number of subjects: 64
Study 23760160 — intervention group
Group type: COMPARATOR
Intervention: Sperm freezing after selection without hypotaurine supplementation (F-S/H-)
Number of subjects: 64
Study 23760160 — intervention group
Group type: COMPARATOR
Intervention: Sperm freezing after selection with hypotaurine supplementation (F-S/H+)
Number of subjects: 64
Study 21443271 — intervention group
Group type: EXPERIMENTAL
Intervention: Crotalidae polyvalent immune Fab (IV administration)
Number of subjects: 0
Study 19539252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1057
Study 19539252 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 1057
Study 16939570 — intervention group
Group type: EXPERIMENTAL
Intervention: Apligraf
Number of subjects: 10
Study 16939570 — intervention group
Group type: EXPERIMENTAL
Intervention: Apligraf dermis only (without epidermis)
Number of subjects: 10
Study 16939570 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane film
Number of subjects: 10
Study 15521841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13-15 mg/kg/day) + Mycophenolate mofetil (1000 mg b.d.)
Number of subjects: 25
Study 15521841 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (13-15 mg/kg/day)
Number of subjects: 25
Study 10966090 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) as a conceptual model for generating interventions
Number of subjects: 0
Study 10966090 — intervention group
Group type: COMPARATOR
Intervention: CQI as a general management philosophy
Number of subjects: 0
Study 9254071 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal containing 63 g fat and 150,000 IU vitamin A
Number of subjects: 49
Study 8485018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR (200 mg levodopa/50 mg carbidopa)
Number of subjects: 9
Study 8485018 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar CR (100 mg levodopa/25 mg benserazide)
Number of subjects: 9
Study 8485018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2442994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozine (600 to 900 mg/day in 3 equally divided doses)
Number of subjects: 26
Study 2442994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozine plus Propranolol (40 mg, 3 times daily)
Number of subjects: 26
Study 2442994 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg, 3 times daily)
Number of subjects: 26
Study 2442994 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 26
Study 2442994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozine plus Propranolol
Number of subjects: 26
Study 2442994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozine
Number of subjects: 26
Study 2442994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Ethmozine plus Propranolol)
Number of subjects: 26
Study 2442994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozine or combination therapy
Number of subjects: 26
Study 2442994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular function assessment
Number of subjects: 26
Study 31552541 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy (PPT)
Number of subjects: 60
Study 31552541 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (Control)
Number of subjects: 60
Study 29543126 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension-training movement program (6 weeks, two 1-hour sessions per week)
Number of subjects: 28
Study 29543126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 27565230 — intervention group
Group type: COMPARATOR
Intervention: Inseminated
Number of subjects: 20
Study 27565230 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced ovulation/inseminated (750 IU eCG, 500 IU hCG)
Number of subjects: 20
Study 27565230 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulated/inseminated (1500 IU eCG, 1000 IU hCG)
Number of subjects: 20
Study 25473210 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejuran®
Number of subjects: 72
Study 25473210 — intervention group
Group type: COMPARATOR
Intervention: Yvoire‐Hydro®
Number of subjects: 72
Study 23787062 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care (CSC)
Number of subjects: 163
Study 23787062 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 163
Study 20645010 — intervention group
Group type: COMPARATOR
Intervention: SLN negative (n = 1988)
Number of subjects: 2335
Study 20645010 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN-only positive (n = 296)
Number of subjects: 2335
Study 20645010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SLN and NSN positive (n = 51)
Number of subjects: 2335
Study 19337387 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (4.5 g/d)
Number of subjects: 0
Study 19337387 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (3.0 g/d)
Number of subjects: 0
Study 19337387 — intervention group
Group type: COMPARATOR
Intervention: Salsalate (maximum tolerable dose, no tinnitus)
Number of subjects: 0
Study 19337387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16617028 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ePTFE vascular grafts (n=130)
Number of subjects: 283
Study 16617028 — intervention group
Group type: COMPARATOR
Intervention: Standard ePTFE vascular grafts (n=135)
Number of subjects: 283
Study 12748028 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 300
Study 10986713 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative 'end to end' surgery
Number of subjects: 73
Study 10986713 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair
Number of subjects: 73
Study 10986713 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 73
Study 10986713 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-operated patients)
Number of subjects: 73
Study 8970352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (LDD) 3 micrograms/kg/min
Number of subjects: 16
Study 8970352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7948157 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention programme
Number of subjects: 221
Study 7948157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 221
Study 3361170 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (1 mg/kg, 4 times every 2.5 hours), dexamethasone (3.8 mg, 4 times every 2.5 hours), antihistamine (10 mg, 2 times every 5 hours)
Number of subjects: 0
Study 3361170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiemetic agents)
Number of subjects: 0
Study 3361170 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiemetic agents
Number of subjects: 0
Study 31917608 — intervention group
Group type: EXPERIMENTAL
Intervention: DL suture‐bridge repair
Number of subjects: 70
Study 31917608 — intervention group
Group type: COMPARATOR
Intervention: SL suture‐bridge repair
Number of subjects: 70
Study 31917608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 29502350 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal protein-enriched, dietary fiber-fortified bar (PFB)
Number of subjects: 30